China NT Pharma and Hilong raise a combined $342 million

Investors respond well to the Hong Kong IPOs of China NT Pharma and Hilong, helping them to raise a total of $342 million.
China NT Pharma's Suzhou factory
China NT Pharma's Suzhou factory

China NT Pharma Group raised HK$1.62 billion $208 million in a Hong Kong IPO last week, while Hilong Holdings pocketed HK$1.04 billion $134 million after a failed first attempt.

Both companies priced their shares at a discount to industrial peers. NT Pharma, a Shanghai-based supply chain and sales service provider for vaccines, sold 357 million shares at HK$4.54 each, the bottom end of an indicated price range that went up to HK$6. The final price translated into a price-to-earnings PE ratio of 16.4 times, based on the company’s 2011 projected earnings. That is a deep discount to its close competitor China Medical System...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222